DEXWireNews

$ZYNE Plenty of time to get into Zynerba Pharma

Long
NASDAQ:ZYNE   None
Don't worry that you missed out on this initial move in the price, still plenty of room to run for ZYNERBA PHARMA, which specializes in the development and commercialism of cannabis treatments for conditions ranging from Epilepsy and Osteoarthritis. Although the stock has had a considerable move this month, it is still a low cap company with huge potential, so maybe no need to rush in but it is a long term investment, with a small allocation of capital for us.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >> link-to.app/dexwirenews

2) Join our Telegram >> t.me/DEXWireNews

3) Join us on WhatsApp >> dexwirenews.com/WhatsApp

4) Follow @DEXWireNews on Social Media
Clause de non-responsabilité

Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.